Bruker Corporation (BRKR) Receives $27.00 Consensus Price Target from Brokerages
Shares of Bruker Corporation (NASDAQ:BRKR) have been assigned a consensus recommendation of “Hold” from the fourteen research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $27.00.
Several research analysts have recently commented on the company. BidaskClub upgraded Bruker Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. Barclays PLC reiterated an “equal weight” rating and issued a $30.00 price objective (up previously from $26.00) on shares of Bruker Corporation in a report on Monday, July 17th. Cowen and Company reiterated a “hold” rating and issued a $29.00 price objective on shares of Bruker Corporation in a report on Friday, July 14th. Wells Fargo & Company downgraded Bruker Corporation from a “market perform” rating to an “underperform” rating in a report on Wednesday, July 12th. Finally, Zacks Investment Research upgraded Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Thursday, July 6th.
In other Bruker Corporation news, CEO Frank H. Laukien purchased 2,335 shares of Bruker Corporation stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $27.39 per share, for a total transaction of $63,955.65. Following the acquisition, the chief executive officer now directly owns 37,791,386 shares in the company, valued at $1,035,106,062.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the transaction, the vice president now owns 60,524 shares in the company, valued at approximately $1,813,904.28. The disclosure for this sale can be found here. 35.20% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in BRKR. Acrospire Investment Management LLC boosted its position in Bruker Corporation by 496.1% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 3,185 shares in the last quarter. SG Americas Securities LLC bought a new stake in Bruker Corporation during the 2nd quarter valued at approximately $111,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Bruker Corporation by 11.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after acquiring an additional 467 shares in the last quarter. Smithfield Trust Co. bought a new stake in Bruker Corporation during the 2nd quarter valued at approximately $138,000. Finally, The Manufacturers Life Insurance Company boosted its position in Bruker Corporation by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 331 shares in the last quarter. Institutional investors own 65.42% of the company’s stock.
Shares of Bruker Corporation (BRKR) traded down 0.27% during midday trading on Friday, hitting $30.04. The stock had a trading volume of 88,360 shares. The firm’s 50-day moving average price is $28.54 and its 200-day moving average price is $26.53. The stock has a market cap of $4.77 billion, a price-to-earnings ratio of 29.95 and a beta of 1.10. Bruker Corporation has a 1-year low of $19.59 and a 1-year high of $30.23.
Bruker Corporation (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The firm had revenue of $414.90 million for the quarter, compared to the consensus estimate of $384.75 million. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.20 earnings per share. Analysts forecast that Bruker Corporation will post $1.12 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 22nd. Investors of record on Tuesday, September 5th will be issued a dividend of $0.04 per share. The ex-dividend date is Thursday, August 31st. This represents a $0.16 dividend on an annualized basis and a yield of 0.53%. Bruker Corporation’s dividend payout ratio is presently 16.00%.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.